ARA Aclara Resources Inc

ART Advanced Research Technologies Inc. ("ART") (TSX: ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, will be featured in several scientific research presentations based on ART's SoftScan® optical imaging device, Optix® in vivo fluorescence optical imaging system, and Fenestra® imaging agent for microCT, at the World Molecular Imaging Congress (WMIC), being held at the Palais des congres in Montreal, Canada, from September 23 to 26, 2009.

Thursday, September 24, 2009 - 4:00 PM to 5:30 PM

Poster Presentation Number: 1088. Quantitative in vivo 3D fluorescence lifetime imaging of a liver-specific agent. G. Ma; D. Huang; M. Piche; M. Jean-Jacques; S.Fortier; M. Khayat.

Poster Presentation Number: 0300. Molecular imaging of pancreatic beta-cell mass: An antibody mediated optical imaging approach. D. Vats; F. Stuker; K. Dikaiou; H. Wang; H. Matile; C. Migliorini; M. Rudin.

Poster Presentation Number: 1215. Multimodal Molecular Imaging of Brain Cancer Using Nanoparticles Functionalized with IGFBP7 Single Domain Antibody. H. Albaghdadi; U. Iqbal; R. Mackenzie; D. Celine; T. Veres; D. Stanimirovic; B. Blasiak; B. Tomanek; G. Sutherland; A. Abulrob.

Poster Presentation Number: 1283. Exploring Novel Optical Imaging Methods for Quantifying Muscle Damage and Inflammation in Mouse Models of Muscular Dystrophy. A.R. Baudy; E. Hoffman; K. Nagaraju.

Poster Presentation Number: 1030. Early Detection of Metastasis Tumors in Mouse Liver Model Using Gated Small Animal FDG PET and Contrast CT Images. S. Woo; G. Cheon; K. Kim; T. Lee; J. Jung; Y. Lee; J. Kang; J. Park; J. Kim; J. Kim; S. Lim.

Poster Presentation Number: 0700. Liposome Contrast Agent for CT-based Detection and Localization of Neoplastic and Inflammatory Lesions in Rabbits: Validation with FDG-PET and Histology. J. Zheng; C. Allen; D.C.Vines; S. Serra; M. Charron; D.A. Jaffray.

Friday, September 25, 2009 - 4:00 PM to 5:30 PM

Poster Presentation Number: 1119. Molecular Imaging using Nanotubes and a Clinical Optical Breast Imaging System. S.M. Van de Ven; N. Mincu; J. Brunette; G. Ma; M. Khayat; D.M. Ikeda; S.S. Gambhir.

Poster Presentation Number: 1005. Micro-CT small animal imaging enhanced by Fenestra LC and meglumine diatrizoate. S. Zhu; J. Tian; X. Ma; X. Zhang; G. Yan.

Poster Presentation Number: 1006. Negative Contrast Enhancement Enables Visualization of Intraperitoneal Tumors in Mice Using CT. M. Rampurwala; M.K. Ravoori; W. Wei; V. Johnson; R. Vikram; V. Kundra.

Saturday, September 26, 2009

1:00 PM to 2:30 PM

Oral Presentation Number: 0217. Quantitative Dynamic SPECT/CT Imaging of Atherosclerotic Plaques in ApoE-/- Mice. B.M. Tsui; J. Yu; Y. Wang; G.S. Mok; S. Nimmagadda; D. Bedja; K.L. Gabrielson; F. Bengel; M. Pomper.

Oral Presentation Number: 0200. Replacing Vascular Corrosion Casting by in-vivo uCT Imaging for Building 3D Cardiovascular Models in Mice. B. Vandeghinste; B. Trachet; M. Renard; C. Casteleyn; S. Deleye; P. Joye; S. Vandenberghe; S.G. Staelens; P. Segers; B. Loeys.

4:00 PM to 5:30 PM

Poster Presentation Number: 0512. Whole-body fluorescence lifetime imaging of human melanoma metastases in mice using Green Fluorescence Protein (GFP). D. Huang; M. Piche; M. Jean-Jacques; G. Ma; M. Khayat.

Poster Presentation Number: 0511. Early detection of human breast cancer MCF-7 using anti-EpCAM antibody conjugated with Cy5.5. D. Huang; M. Piche; M. Jean-Jacques; G. Ma; M. Khayat.

Poster Presentation Number: 1268. Molecular Imaging of Brain Tumor Vessels Using Anti-IGFBP7 Single Domain Antibody Constructs. U. Iqbal; H. Albaghdadi; R. Mackenzie; B. Tomanek; G. Sutherland; D. Stanimirovic; A. Abulrob.

Poster Presentation Number: 0962. Multimodal therapeutic monitoring of HSV1-tk/GCV gene therapy using I-124-FIAU-PET, bioluminescence and liver contrast enhance CT in orthotopic hepatoma model. T. Lee; S. Woo; J. Jung; K. Woo; W. Chung; J. Kang; Y. Lee; K. Kim; G. Cheon; S. Lim.

Full texts of the abstracts can be obtained through the WMIC Itinerary Planner (http://wmicmeeting.org/dev/content/view/74/104/).

About ART

ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. The Optix® optical molecular imaging system, designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is used by industry and academic leaders worldwide. The SoftScan® optical medical imaging device is designed to improve the diagnosis and treatment of breast cancer. Finally, the Fenestra® line of molecular imaging contrast products provides image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities. ART is commercializing some of these products in a global strategic alliance with GE Healthcare, a world leader in mammography and imaging. ART's shares are listed on the TSX under the ticker symbol ARA. For more information on ART, visit our website at www.art.ca.

This press release may contain forward-looking statements subject to risks and uncertainties that would cause actual events to differ materially from expectations. These risks and uncertainties are described in the most recent Annual Information Form and the financial statements for the year ended December 31, 2008, available on SEDAR (www.sedar.com).

Contacts: ART Advanced Research Technologies Inc. Dino DiCamillo Vice President, Global Sales and Marketing, Preclinical Imaging ddicamil@art.ca ART Advanced Research Technologies Inc. Jacques Bedard Chief Financial Officer 514-832-0777 jbedard@art.ca www.art.ca